Investor Resources
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022....
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for...
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that it has closed on the...
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 28, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that its subsidiary...
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – August 16, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...